A Prospective Cohort Study assessing the feasibility, efficacy and safety of Cardiac Stereotactic Body Radiotherapy (SBRT) in patients with Ventricular Tachycardia (VT)

Metro South Hospital0 sites10 target enrollmentAugust 4, 2022

Overview

No summary available.

Registry

who.int

Start Date

August 4, 2022

End Date

TBD

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

Metro South Hospital

•Documented sustained ventricular tachycardia (VT) with at least 3 episodes of VT in 12 months prior to enrollment
•Require at least 1 anti\-arrhythmic medication
•Failed at least 1 invasive catheter ablation procedure, or have contraindications to invasive catheter ablation
•Assessed as able to tolerate radiotherapy planning, immobilisation and treatment as deemed by the radiation oncologist
•Willing and able to provide informed consent

•Previous radiotherapy to the chest with any radiation dose to the heart
•Advanced heart failure (NYHA Class IV)
•High\-volume myocardial scar substrate to such an extent that treatment with Stereotactic Body Radiotherapy (SBRT) is deemed unsafe by the radiation oncologist
•Ventricular Tachycardia (VT) deemed not to be related to a definable myocardial scar
•Competing comorbidities (unrelated to VT) which limit life expectancy to less than 6 months.
•Must not be pregnant and/or breastfeeding if female; must have a negative pregnancy test within 7 days of study enrollment.
•Implantable Cardiac Defibrillator (ICD) implanted less than 6 weeks prior
•Renal failure or allergy precluding administration of Intravenous (IV) gadolinium
•Computer Tomography (CT) IV contrast allergy
•Any concurrent anti\-neoplastic therapy